Ancillary testing in prostate cancer

From Libre Pathology
Jump to navigation Jump to search

Ancillary testing in prostate cancer is evolving. Prostate cancer panel redirect here.

PARP inhibitors

  • Poly(ADP-ribose) polymerases (PARP) inhibitors, e.g. olaparib, target BRCA1/2 mutations.[1]

Molecular panel:

MMR testing

  • MMR deficiency is seen in approximately 3% of prostate cancers.[2]


See also

References

  1. ↑ Dziadkowiec KN, Gąsiorowska E, Nowak-Markwitz E, Jankowska A (December 2016). "PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting". Prz Menopauzalny 15 (4): 215–219. doi:10.5114/pm.2016.65667. PMC 5327624. PMID 28250726. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5327624/.
  2. ↑ Abida W, Cheng ML, Armenia J, Middha S, Autio KA, Vargas HA, Rathkopf D, Morris MJ, Danila DC, Slovin SF, Carbone E, Barnett ES, Hullings M, Hechtman JF, Zehir A, Shia J, Jonsson P, Stadler ZK, Srinivasan P, Laudone VP, Reuter V, Wolchok JD, Socci ND, Taylor BS, Berger MF, Kantoff PW, Sawyers CL, Schultz N, Solit DB, Gopalan A, Scher HI (April 2019). "Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade". JAMA Oncol 5 (4): 471–478. doi:10.1001/jamaoncol.2018.5801. PMC 6459218. PMID 30589920. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459218/.
Retrieved from "https://librepathology.org/w/index.php?title=Ancillary_testing_in_prostate_cancer&oldid=52200"